Credit Suisse AG cut its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 14.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,331 shares of the company’s stock after selling 2,528 shares during the quarter. Credit Suisse AG’s holdings in Karyopharm Therapeutics were worth $197,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Teza Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics in the 1st quarter valued at $169,000. American International Group Inc. grew its stake in Karyopharm Therapeutics by 20.9% during the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after buying an additional 2,836 shares during the last quarter. Parametric Portfolio Associates LLC grew its stake in Karyopharm Therapeutics by 38.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 27,988 shares of the company’s stock worth $359,000 after buying an additional 7,789 shares during the last quarter. Teachers Advisors LLC grew its stake in Karyopharm Therapeutics by 15.0% during the 4th quarter. Teachers Advisors LLC now owns 41,436 shares of the company’s stock worth $389,000 after buying an additional 5,419 shares during the last quarter. Finally, Swiss National Bank grew its stake in Karyopharm Therapeutics by 10.9% during the 1st quarter. Swiss National Bank now owns 40,850 shares of the company’s stock worth $525,000 after buying an additional 4,000 shares during the last quarter. Institutional investors and hedge funds own 58.97% of the company’s stock.

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded up 2.46% on Friday, reaching $10.81. The company had a trading volume of 203,958 shares. The firm’s 50 day moving average is $9.07 and its 200 day moving average is $9.86. Karyopharm Therapeutics Inc. has a 12 month low of $6.27 and a 12 month high of $14.63. The firm’s market capitalization is $509.56 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, meeting the consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. The firm’s quarterly revenue was down 95.0% on a year-over-year basis. During the same period last year, the firm earned ($0.84) EPS. On average, equities research analysts expect that Karyopharm Therapeutics Inc. will post ($2.68) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/09/credit-suisse-ag-has-197000-stake-in-karyopharm-therapeutics-inc-kpti.html.

Several research analysts recently weighed in on KPTI shares. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research note on Monday, May 15th. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 25th. Robert W. Baird restated an “outperform” rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, July 4th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Thursday, July 6th. Finally, Jefferies Group LLC restated a “buy” rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $15.88.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.